期刊文献+

抗流感病毒药物和病毒耐药性 被引量:9

Anti-influenza virus agents and drug resistance
下载PDF
导出
摘要 M2蛋白通道阻断剂金刚烷胺(amantadine)和金刚乙胺(rimantadine)在体内外均可迅速产生耐药和交叉耐药,机制是源于M2蛋白转膜区突变,涉及的5个主要氨基酸残基是26、27、30、31和34位。神经氨酸酶抑制剂磷酸奥司他韦(oseltamivir)、扎那米韦(zanamivir)和帕那米韦(paramivir)耐药的突变位点发生在病毒A型NA的119、274、292位点及B型152位点。目前尚无一种流感病毒对所有的化疗药物多重耐药。新的神经氨酸酶抑制剂和作用于其他靶点的新药尚处于临床前试验阶段。 Resistance and cross-resistance of influenza A virus to M2 inhibitors adamantane and rimantadine can emerge ra- pidly during treatment in vitro and in vivo. A single point mutation in the codons for amino acids at positions 26, 27, 30, 31, or 34 of the M2 protein can confer the resistance and cross-resistance to both amantadine and rimantadine. Drug resistance emergency in use of neuraminidase (NA) inhibitors, osehamivir, zanamivir and paramivir is caused by the change of the NA at residues 119, 274, 292 (type A) and 152 (type B). So far no any influenza virus strain has been found to be resistant to all chemotherapeutic drugs. The studies on new NA inhibitors and drugs directed to other targets are now in trial period.
作者 张兴权 范江
出处 《传染病信息》 2011年第2期124-128,共5页 Infectious Disease Information
关键词 神经氨酸酶 酶抑制剂 抗药性 基因突变 neuraminidase enzyme inhibitors drug resistance gene mutation
  • 相关文献

参考文献1

二级参考文献15

  • 1Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine 2007; 25:5637-5644.
  • 2Skeik N, Jabr FI. Influenza viruses and the evolution of avian influenza virus H5N1. IntJInfectDis 2008; 12:233-238.
  • 3Taubenberger JK, Reid AH, Lourens RM, et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-893.
  • 4Tumpey TM, Maines TR, Hoeven NV, et al. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 2007; 315:655-659.
  • 5Russell RJ, Haire LF, Stevens D J, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-49.
  • 6Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-4520.
  • 7Mitrasinovic PM. On the structure-based design of novel inhibitors of H5N1 influenza A virus neurarninidase (NA). Biophys Chem 2009; 140:35-38.
  • 8Wade RC. 'Flu' and structure-based drug design. Structure 1997; 5:1139-1145.
  • 9Rameix-Welti MA, Enouf V, Cuvelier F, et al. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008: 4:e1000103.
  • 10Mihajlovic ML, Mitrasinovic PlVl. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys Chem 2008; 136:152-158.

共引文献5

同被引文献105

引证文献9

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部